Related Experiment Video
Updated: May 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Current evidence about intermittent androgenic deprivation in prostate cancer]
J D López1, G López-Fontana, R López-Fontana
1Cátedra Urología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo. Clínica Andina de Urología, Mendoza, Argentina.
Objectives:
To identify clinical application of intermittent hormonotherapy in prostatic carcinoma.
Material And Methods:
We conducted a systematic review in MEDLINE database and COCHRANE Library using the words MeSH "prostate cancer, androgenic deprivation and intermittent". There were included those with the best level of evidence and published in the last 10 years.
Results:
Intermittent hormone therapy is one of the tools we use in urological armamentarium for special circumstances. This analysis highlights: possibility to regain sexual function during the period of suspension of treatment (time off) due to the recovery of testosterone levels also demonstrating an improvement in symptoms, decreased costs preserving the same oncological control compared to complete androgenic deprivation.
Conclusions:
There is still controversy about the benefits in quality of life and the emergence of long-term side effects typical of continuous hormonal therapy. Therefore and until now, we should only propose intermittent therapy in selected patients.
Related Concept Videos
Infertility in Males
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

